Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
Agreement--Chai’s second with Lilly--enables biotechs in early biologics discovery to evaluate Chai’s miniprotein design suite
Chai Discovery, the AI company engineering models to discover new molecules, today announced that certain Chai Discovery frontier AI model capabilities will be made available to companies participating in the Lilly TuneLab platform.
Lilly TuneLab is a collaborative AI/ML drug discovery platform created by Lilly to provide biotechs companies access to models trained on years of Lilly's proprietary research data.
"Our collaboration with Lilly TuneLab brings important design capabilities to biotech companies working in early discovery,” said Joshua Meier, co-founder and CEO of Chai Discovery. “Our latest models can design high-affinity binders to targets that have stumped prior computational approaches, and they can do it in hours, not months.”
